Federal regulators invite industry, researchers, and lobbyists to closed-door meetings on clinical AI

August 5, 2026 - 17:21

Federal health regulators have quietly hosted a series of private meetings with technology firms, academic researchers, and industry lobbyists to shape the future of clinical artificial intelligence. The sessions, which were not open to the public, focused on how to speed up the safe use of AI tools in hospitals and doctor offices.

The agency behind the talks is the U.S. Food and Drug Administration, which oversees medical devices and software used in patient care. According to people familiar with the matter, the closed-door discussions covered topics like how to validate AI algorithms that learn from patient data, how to monitor them after they are deployed, and what evidence should be required before a new tool gets approved.

Industry representatives pushed for faster review times and clearer rules, arguing that current regulations were built for older, static software and do not fit modern machine learning systems that update themselves. Researchers, on the other hand, stressed the need for independent testing and transparency, warning that some AI tools have shown bias or failed in real-world settings.

The FDA has not released detailed notes from the meetings, which has drawn criticism from patient advocacy groups. They say decisions about AI in medicine should be made in the open, especially as hospitals increasingly rely on algorithms for tasks like reading X-rays, predicting patient deterioration, and suggesting treatment plans.

Agency officials say the goal is to create a flexible framework that encourages innovation while protecting patients. They have not announced a timeline for new guidance, but insiders expect draft recommendations within the next year. For now, the closed-door approach has left many in the healthcare community guessing about what comes next.